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ABSTRACT 
Novel drug delivery systems are now a days is creating a new interest in development of drug deliveries. Vesicular drug delivery system is also a 
part of these novel drug delivery systems. TDDS is the permeability of the skin, it is permeable to small molecules, lipophilic drug and highly 
impermeable to the macromolecules and hydrophilic drugs. Recent approaches have resulted in design of two vesicular carriers, ethosomes and 
ultra flexible lipid based elastic vesicles, transferosomes. Transferosomes have recently been introduced, which are capable of transdermal 
delivery of low as well as high molecular weight drugs. This offers several potential advantages over conventional routes like avoidance of first 
pass metabolism, predictable and extended duration of activity, minimizing undesirable side effects, utility of short half life drugs, improving 
physiological and pharmacological response and have been applied to increases the efficiency of the material transfer across the intact skin, by 
the use of penetration enhancers, iontophoresis, sonophoresis and use of colloidal carriers such as lipid vesicles (liposomes & proliposomes) and 
non-ionic surfactant vesicles (niosomes & proniosomes). It is suitable for controlled and targeted drug delivery and it can accommodate drug 
molecules with wide range of solubility. Due to its high deformability it gives better penetration of intact vesicles. They are biocompatible and 
biodegradable as they are made from natural phospholipids and have high entrapment efficiency. The preparation variables are depending upon 
the procedure involved for manufacturing of formulation and the preparation procedure was accordingly optimized and validated. 
Characterization of transferosomes can be done to know the vesicle size, morphology, drug content, entrapment efficiency, penetration ability, 
occlusion effect, surface charge, in vitro drug release, in vitro skin penetration etc., It increases stability of labile drugs and provides control 
release. Transferosomes thus differs from such more conventional vesicles primarily by its softer, more deformable, better adjustable artificial 
membrane.  
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INTRODUCTION  
In recent years, research scenario goes toward the 
development of new type of drug delivery system with the 
objective of high therapeutic activity along with patient 
compliance. Many drug delivery systems are developed with 
improved therapeutic activity, but some complications arise 
with some delivery systems are not as such overcomes. 
Orally administered drugs experience a hostile environment 
in the gastrointestinal (GI) tract, where most drugs are 
degraded in variable pH conditions, or face solubility issues 
and most importantly first-pass metabolism. In case of 
parenteral preparation, disadvantages are a lack of drug 
reversal, hypersensitivity reaction, risk of infection, emboli 
and cost. Some drugs much bitter in taste, swallowing of 
such a bitter medication in oral delivery and pain associated 
due to needle in parenteral delivery make them less patient 
compliance1. From last few decades, considerable attention 
has been focused on the development of topical delivery of 
drugs because a number of advantages with this route. Skin 
in an average adult body covers a surface of approximately 2 
m2 and total weight of 3 kg; it receives about one-third of the 
blood circulating among the body. Topical drug delivery 
means the application of drug to skin for localized effect and 
in transdermal drug delivery system (TDDS) skin is used as a 
potential route for the delivery of systemic action of drugs. 
TDDS is one of the systems with high patient compliance. 
Some potential advantages of transdermal route found over 
other conventional routes such as oral- and parenteral-like 
avoidance of first-pass metabolism, predictable and 
extended duration of activity, minimizing undesirable side 
effects, utility of short half-life drugs, improving 
physiological and pharmacological response, avoiding the 
fluctuation in drug levels, inter- and intra-patient variations 
Chaurasiya et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(1):279-285 
ISSN: 2250-1177                                                                                  [280]                                                                                 CODEN (USA): JDDTAO 
and most importantly, it provides patients convenience2,3. 
However, it also has some disadvantages such as possibility 
of local irritation effect, erythema, itching and low 
permeability in the stratum corneum. A major obstacle to 
dermal and transdermal drug delivery is the permeation 
characteristics of the stratum corneum, which limits drug 
transport, making this route of administration frequently 
insufficient for medical use4. Stratum corneum is the top 
layer of the epidermis consists of keratinized, flattened 
remnants of once actively dividing epidermal cells, 
impermeable to water and behaves as a tough flexible 
membrane. Many technologies and systems have been 
investigated to evade this barrier including electrophoresis, 
iontophoresis, chemical permeation enhancers, 
microemulsions, sonophoresis, as well as utilizing vesicular 
systems such as liposome, niosomes, ethosomes, and 
transfersomes, one of the most promising techniques is to 
formulate novel vesicular carriers for delivery through the 
skin as it delivered drug at sustained or controlled manner5-
10. Among all these transfersomes appear promising. A new 
type of vesicular drug carrier system called transfersome. 
The term transfersomes (Fig 1) and the underlying concept 
were introduced in 1991 by Gregor Cevc. In broadest sense, a 
transfersomes is a highly adaptable and stress-responsive, 
complex aggregate possessing an aqueous core surrounded 
by a complex of lipid bilayer11,12. Transfersome is a term 
registered as a trademark by the German Company IDEA AG 
and used by it to refer to its proprietary drug delivery 
technology. The name means carrying body and is derived 
from the Latin word transferred meaning to carry across and 
the Greek word soma for a body. A transfersome carrier is an 
artificial vesicle designed to be like a cell vesicle or a cell 
engaged in exocytosis, and thus suitable for controlled and 
potentially targeted, drug delivery13. Most suitable form of 
transfersome is an ultra deformable vesicle possessing an 
aqueous core surrounded by the complex lipid bilayer. In 
terms of delivering of drugs through transdermal route, 
there are some problems encountered with some other 
vesicular systems such as poor skin permeability, breaking 
of vesicles, leakage of drug and aggregation and fusion of 
vesicles. To overcome all the above problems, a new type of 
vesicular carrier has been developed called transfersome 
which is capable of transdermal delivery of low as well as 
high molecular weight drugs. Transfersomes are artificial 
vesicles, and they are more deformable than standard 
liposomes. Transfersomes have been reported to enhance 
the transdermal delivery of drugs when applied onto the 
skin non occlusively12, 14-17. 
 
Figure 1: Deformable transfersomes vesicle 
ADVANTAGES 
 Transdermal medication delivers a steady infusion of a 
drug over an extended period of time. 
 An equivalent therapeutic effect can be elicited via 
transdermal drug input with a lower daily dose of the 
drug than is necessary. 
 Self administration is possible with these systems. 
 They are easily and rapidly identified in emergencies (e.g. 
unresponsive, unconscious or comatose patient) because 
of their physical presence, features and identifying 
markings. 
 They can be used for drugs with narrow therapeutic 
window. 
 Longer duration of action resulting in a reduction in 
dosing frequency. 
 Increased convenience to administer drugs which would 
otherwise require frequent dosing. 
 Improved bioavailability. 
 More uniform plasma levels and maintain plasma 
concentration of potent drugs. 
 Reduced side effects and improved therapy due to 
maintenance of plasma levels up to the end of the dosing 
interval. 
 Flexibility of terminating the drug administration by 
simply removing patch from the skin. 
 Improved patient compliance and comfort via non-
invasive, painless and simple application. 
 Avoid inter and intra patient variation and enhance 
therapeutic efficacy. 
DISADVANTAGES 
 Many drugs especially drugs with hydrophilic structures 
permeate the skin too slowly to be of therapeutic 
benefit. 
 The barrier function of the skin changes from one site to 
another on the same person, from person to person and 
also with age. 
 Drug molecule must be potent because patch size limits 
amount that can be delivered. 
 Not suitable for high drug doses. 
 Adhesion may vary with patch type and environmental 
conditions. 
 Skin irritation and hypersensitivity reactions may occur. 
 Drugs that require high blood levels cannot be 
administered. 
 Along with these limitations the high cost of the product 
is also a major drawback for the wide acceptance of this 
product. 
 Transfersomes are chemically unstable because of 
oxidative degradation make its predisposition. 
 Purity of natural phospholipids is another criterion for 
achieve for adoption of transfersomes as drug delivery 
vehicles18-20. 
WHY ONLY TRANSFERSOMES FOR SKIN 
Transfersomes are advantageous as phospholipids vesicles 
for transdermal drug delivery. Because of their self-
optimized and ultra flexible membrane properties, they are 
able to deliver the drug reproducibly either into or through 
the skin, depending on the choice of administration or 
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application, with high efficiency. The vesicular transfersomes 
are more elastic than the standard liposomes and thus well 
suited for the skin penetration. Transfersomes overcome the 
skin penetration difficulty by squeezing themselves along the 
intracellular sealing lipid of the stratum corneum. These are 
characteristic with transfersomes, because of the high vesicle 
deformability which permits the entry due to the mechanical 
stress of surrounding, in a self-adapting manner. Flexibility 
of transfersomes membrane is governed by mixing suitable 
surface-active components in the proper ratios with 
phospholipids 21. The resulting flexibility of transfersome 
membrane minimizes the risk of complete vesicle rupture in 
the skin and allows transfersomes to follow the natural 
water gradient across the epidermis, when applied under 
non-occlusive condition. Transfersomes can penetrate the 
intact stratum corneum spontaneously along two routes in 
the intracellular lipid that differ in their bilayers properties. 
Bangham discovered liposomes in 1963 and since then 
vesicular systems have attracted increasing attention. But 
recently it has become evident that classic liposomes are of 
minor values in terms of penetration. Confocal microscopic 
studies have shown that intact liposomes are not able to 
penetrate into granular layer of epidermis but, they rather 
remain on the upper layer of stratum corneum. The 
modification of the vesicular compositions or surface 
properties can adjust the drug release rate and the 
deposition to the target site 22-24. 
COMPOSITION OF TRANSFERSOMES 
The transfersome is composed of two main aggregates 
namely, 
1. Firstly, an amphipathic ingredient (phosphatidylcholine), 
in which the aqueous solvents self-assemble into lipid 
bilayer that closes into a simple lipid vesicle. 
2. Secondly, a bilayer softening component (such as a 
biocompatible surfactant oramphiphile drug) that increases 
lipid bilayer flexibility and permeability25. 
The resulting, flexibility and permeability optimized, 
transfersome vesicle can therefore adapt its shape easily and 
rapidly, by adjusting local concentration of each bilayer 
component to the local stress experienced by the bilayer. 
Therefore, the transfersome thus differs from such more 
conventional vesicle primarily by its "softer", more 
deformable, and better adjustable artificial membrane Table 
1.
 
Table 1: Different additives used in formulation of transfersomes 
S.No Class Example Use 
1 Phospholipids Soya phosphatidyl choline, egg phosphatidyl choline, 
dipalmitoylphosphatidyl choline 
Vesicles forming component 
2 Surfactants Sod.cholate, Sod.deoxycholate, Tween-80, Span-80, Tween 20 Vesicles forming component 
3 
4 
Solvents 
Buffering agent 
Ethanol, methanol, isopropyl alcohol, chloroform  
Saline phosphate buffer (pH 6.4), phosphate buffer pH 7.4 
As a solvent, 
As a hydrating medium 
5 Dye Rhodamine-123 Rhodamine-DHPE Fluorescein-DHPE Nile-red For CSLM study 
 
METHODS FOR PREPARATION OF TRANSFERSOME 
1. Vortexing-sonication method  
In this method, mixed lipids (i.e. phospha-tidylcholine, EA 
and the therapeutic agent) are blended in a phosphate buffer 
and vortexed to attain a milky suspension. The suspension is 
sonicated, followed by extrusion through poly-carbonate 
membranes.  
2. Suspension homogenization process  
In this process, transfersomes are prepared by mixing an 
ethanolic soybean phosphatidylcholine solution with an 
appropriate amount of edge-active molecule, e.g. sodium 
cholate. This prepared suspension is subsequently mixed 
with Triethanolamine-HCl buffer to yield a total lipid 
concentration. The resulting suspension is sonicated, frozen, 
and thawed for 2 to 3 times.  
3. Modified handshaking process  
In this process, the transfersomes are prepared by modified 
hand shaking, ‘lipid film hydration technique’. Drug, lecithin 
(PC) and edge activator were dissolved in ethanol: 
chloroform (1:1) mixture. Organic solvent was removed by 
evaporation while hand shaking above lipid transition 
temperature (43°C). A thin lipid film was formed inside the 
flask wall with rotation. The thin film was kept overnight for 
complete evaporation of solvent. The film was then hydrated 
with phosphate buffer (pH 7.4) with gentle shaking for 15 
minute at corresponding temperature.  
4. Aqueous lipid suspension process  
In this process, Drug-to-lipid ratio in the vehicles is fixed 
between 1/4 and 1/9. Depending upon the particular 
formulation type, the composition is preferred. This would 
ensure the high flexibility of the vesicle membrane in 
comparison to the standard phosphatidylcholine vesicles in 
the fluid phase. Specifically, vesicles with the size ranging 
from 100-200 nm are prepared by using 
soyphosphatidylcholine with the standard deviation of size 
distribution (around 30%). This formulation could be 
prepared by suspending the lipids in an aqueous phase 
wherein the drug is dissolved.  
5. Centrifugation process  
In this process, phospholipids, surfactants and the drug are 
dissolved in alcohol. Then the solvent is removed by rotary 
evaporation under reduced pressure at 40oC. Final traces of 
solvent are removed under vacuum. Then the deposited lipid 
film is hydrated with the appropriate buffer by centrifuging 
at 60 rpm for 1 hour at room temperature. At room 
temperature, the resulting vesicles are swollen for 2 hours. 
The multi-lamellar lipid vesicles obtained which are further 
sonicated at room temperature 26-28. 
MECHANISM OF ACTION 
Mechanism behind the penetration of transfersome is the 
development of osmotic gradient because while lipid 
suspension applies on skin surface water gets evaporated. 
Transfersomes have strong bilayer deformability and 
therefore they have increased affinity to bind and retain 
water. Dehydration is not happened in case an 
ultradeformable and highly hydrophilic vesicle; it is not 
identical to forward osmosis but may involve in transport 
process related to forward osmosis. Upon application on skin 
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surface (non-occluded), it penetrates skin barrier and 
reaches at the deeper strata (water rich portion), where they 
get hydrated. Then, reach at deeper epidermal layer through 
dehydration of lipid vesicles within the stratum corneum by 
natural transepidermal activity (Fig 2). Therefore, 
transfersome uptake is a function of hydration gradient that 
exists across the epidermis, stratum corneum, and ambient 
atmosphere 29,30. 
 
Figure 2: Penetration pathway of transfersomes 
OPTIMIZATION OF FORMULATION CONTAINING 
TRANSFERSOMES 
There are some process variables such as lecithin, surfactant 
ratio, effect of various solvents, effect of various surfactants, 
and hydration medium. This could affect the preparation and 
properties of the transfersomes. Procedure for preparation 
of transfersomes will accordingly optimize and validate. The 
process variables depend on the procedure for 
manufacturing of formulation. Entrapment efficiency of drug 
is the tool used for optimization. Other variables were kept 
constant at the time of preparation of particular system31. 
CHARACTERIZATION OF TRANSFERSOMES  
The characterization of transfersomes is generally similar to 
liposomes, niosomes and micelles. The following 
characterization parameters have to be checked for 
transfersomes.  
1. Vesicle size distribution and zeta potential 
Dynamic light scattering method (DLS) using a computerized 
inspection system by Malvern Zetasizer used for 
determination of vesicle size, size distribution, and zeta 
potential.  
2. Vesicle morphology  
Photon correlation spectroscopy or DLS method generally 
used for vesicle diameter determination. Prepared sample in 
distilled water was filtered through 0.2 mm membrane filter 
and diluted with filtered saline and then size measurement 
done using photon correlation spectroscopy or DLS 
measurements. Transmission electron microscopy (TEM) 
and phase contrast microscopy can be commonly used for 
visualization of transfersomes vesicles. The stability of 
vesicle can be determined by assessing the size and structure 
of vesicles with respect to time. DLS and TEM used for mean 
size and structural changes, respectively.  
3. Number of vesicles per cubic mm 
This parameter is very important for optimization of 
composition and other process variables. Transfersome 
formulations which are unsonicated are diluted 5 times with 
0.9% sodium chloride solution. Hemocytometer and optical 
microscope are used for further study.  
The transfersomes in 80 small squares are counted and 
calculated using the following formula:  
Total number of transfersomes per cubic mm = (Total 
number of transfersomes counted × dilution factor × 
4000)/total number of squares counted  
4. Entrapment efficiency  
Generally, expressed in terms of % drug entrapment. In this 
method, unentrapped drug first separated using minicolumn 
centrifugation method. After that, the vesicles were 
disrupted using 0.1% Triton X-100 or 50% n-propanol. The 
entrapment efficiency is expressed as:  
Entrapment efficiency = (Amount entrapped/Total amount 
added) × 100  
5. Drug content 
The drug content is determined using one of the 
instrumental analytical methods such as a modified high-
performance liquid chromatography method using an 
ultraviolet detector, column oven, auto sample, pump, and 
computerized analysis program depending on the analytical 
method of the pharmacopoeial drug.  
6. Turbidity measurement 
Nephelometer is one of the methods which generally used 
for turbidity measurement in aqueous solution.  
7. Degree of deformability or permeability measurement 
Permeability study is one of the important and unique 
parameters for characterization in case of transfersomes. 
The deformability study is done by taking pure water as 
standard. Transfersomes preparation is passed through a 
number of pores of known size (through a sandwich of 
different microporous filters, with pore diameter between 
50 and 400 nm, depending on the starting transfersomes 
suspension). Particle size and size distributions are noted 
after each pass by DLS measurements.  
8. Penetration ability 
Fluorescence microscopy can generally use for evaluation of 
penetration ability of transfersomes.  
9. Occlusion effect 
Occlusion of skin is considered to be useful for permeation of 
drug in case of traditional topical preparations. However, the 
occlusion also proves to be harmful for elastic vesicles. 
Hydrotaxis is the major driving force for permeation of 
vesicles through the skin is hydrotaxis (movement in the 
direction) of water, from its relatively dry surface to water 
rich deeper regions. It affects hydration forces as it prevents 
evaporation of water from skin.  
10. Surface charge and charge density 
Surface charge and charge density of transfersomes can be 
determined using zetasizer.  
11. In-vitro drug release 
In vitro drug release study is performed for determining the 
permeation rate. Time needed to attain steady state 
permeation and the permeation flux at steady state and the 
information from in vitro studies are used to optimize the 
formulation before more expensive in vivo studies are 
performed. For determining drug release, transfersomes 
suspension is incubated at 32°C and samples are taken at 
different times and the free drug is separated by minicolumn 
centrifugation. The amount of drug released is then 
calculated indirectly from the amount of drug entrapped at 
zero times as the initial amount (100% entrapped and 0% 
released).  
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12. In vitro skin permeation studies 
Modified Franz diffusion cell with a receiver compartment 
volume of 50 ml and effective diffusion area of 2.50 cm2 was 
used for this study. In vitro drug study was performed using 
goat skin in phosphate buffer solution (pH 7.4). Fresh 
abdominal skin of goat was collected from slaughterhouse 
and used in the permeation experiments. Abdominal skin 
hairs were removed, and the skin was hydrated in normal 
saline solution. The adipose tissue layer of the skin was 
removed by rubbing with a cotton swab. Skin was kept in 
isopropyl alcohol solution and stored at 0-40°C. To perform 
skin permeation study, treated skin was mounted 
horizontally on the receptor compartment with the stratum 
corneum side facing upward toward the donor compartment 
of Franz diffusion cell. The effective permeation area of 
donor compartment exposed to receptor compartment was 
2.50 cm2 and capacity of receptor compartment was 50 ml. 
The receptor compartment was filled with 50 ml of 
phosphate buffer (pH 7.4) saline maintained at 37 ± 0.5°C 
and stirred by a magnetic bar at 100 rpm. Formulation 
(equivalent to 10 mg drug) was placed on the skin, and the 
top of the diffusion cell was covered. At appropriate time 
intervals, 1 ml aliquots of the receptor medium were 
withdrawn and immediately replaced by an equal volume of 
fresh phosphate buffers (pH 7.4) to maintain sink conditions. 
Correction factors for each aliquot were considered in the 
calculation of release profile. The samples were analyzed by 
any instrumental analytical technique.  
13. Physical stability 
The initial drug entrapped (percent) in the formulation was 
determined and was stored in sealed glass ampoules. The 
ampoules were placed at 4 ± 2°C (refrigeration), 25 ± 2°C 
(room temperature), and 37 ± 2°C (body temperature) for at 
least 3 months. Samples from each ampoule were analyzed 
after 30 days to determine drug leakage. Percent drug loss 
was calculated by keeping the initial entrapment of drug as 
100% 32. 
APPLICATION OF TRANSFERSOMES 
1. Delivery of insulin  
Transfersome is one of the successive ways to deliver such 
large molecular weight drugs on the skin. Insulin is generally 
administered by subcutaneous route that is inconvenient for 
patient. Encapsulation of insulin in transfersome 
(transfersulin) overcomes all problems arises with 
conventional insulin delivery. After application of 
transfersulin on the intact skin, therapeutic effect observed 
after 90-180 min, depending on the carrier composition.  
2. Delivery of corticosteroids  
Problems arise with corticosteroids delivery is mask by 
incorporation it into transfersomes. Site specificity and 
overall drug of corticosteroid delivery into skin by 
optimizing the epicutaneously administered drug dose safety 
is achieved by transfersome encapsulation. Dose required for 
biological activity of corticosteroid is less by use of 
transfersomes technology.  
3. Delivery of proteins and peptides 
Transfersomes have been widely used as a carrier for the 
transport of proteins and peptides also safely given by 
means of transfersome technology. Proteins and peptide has 
problem is it is difficult to transfer into the body, are large 
biogenic molecules, GI tract degradation is problem arise 
when given orally. That’s reasons why these peptides and 
proteins still given by means of injectables. A number of 
approaches have been developed to improve this condition. 
Transfersome is somewhat identical to that resulting from 
subcutaneous injection of protein suspension in terms of 
bioavailability. On repeated epicutaneous application, 
transfersome preparation of protein also induced a strong 
immune response. For example, the adjuvant immunogenic 
serum albumin in transfersomes, after several dermal 
challenges, is as active immunologically as is the 
corresponding injected proteo-transfersomes preparations.  
4. Delivery of interferon (INF)  
INF also delivered using transfersome as a carrier, for 
example, leukocyte-derived INF-α is a naturally occurring 
protein having antiviral, antiproliferative, and some 
immunomodulatory effects. Transfersomes as drug delivery 
systems have the potential for providing controlled release 
of the administered drug and increasing the stability of labile 
drugs. Hafer et al. studied the formulation of transfersome 
containing interleukin-2 (IL-2) and INF-α for potential 
transdermal application. They reported delivery of IL-2 and 
INF-α promising by transfersomes insufficient concentration 
for immunotherapy.  
5. Delivery of anticancer drugs  
Transfersome technology provides a new approach for 
cancer treatment, especially skin cancer. Result found to be 
favorable when methotrexate was tried for transdermal 
delivery using transfersome technology.  
6. Delivery of anesthetics 
Application of transfersome containing anesthetics induces a 
topical anesthesia, under suitable conditions, within 10 min. 
Effect when we said in case of pain in sensitivity is nearly as 
strong (80%) as of a comparable subcutaneous bolus 
injection, but transfersomal anesthetics preparation has last 
longer effect.  
7. Delivery of non-steroidal anti-inflammatory drugs 
(NSAIDs)  
Problems arise with most of NSAIDs are a number of GI side 
effects. This can be overcome by transdermal delivery using 
transfersome. Studies have been carried out on diclofenac 
and ketoprofen. Ketoprofen in a transfersome formulation 
gained marketing approval by the Swiss regulatory agency 
(Swissmedic) in 2007; the product is expected to be 
marketed under the trademark “Diractin.” Further 
therapeutic products based on the transfersome technology, 
according to IDEA AG, are in clinical development.  
8. Delivery of herbal drugs  
Herbal drug also delivered by transfersome approach. Xiao-
Ying et al. who shows the better topical absorption of 
transfersomes of capsaicin in comparison to pure 
capsaicin33-39.
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Table 2: Application of transfersomes40 
S.No Name of drug Inference 
1 Curcumin Better permeation for anti-inflammatory activity 
2 Indinavir sulfate Improved influx for activity against acquired immune deficiency syndrome (AIDS) 
3 Ketoprofen Improved penetration for anti-inflammatory activity 
4 
Insulin induce therapeutically significant hypoglycemia with good efficacy and reproducibility  
5 Capsaicin Increase skin penetration 
6 Colchicine Increase skin penetration 
7 
Vincristine 
Increase entrapment efficiency 
and skin permeation  
8 Interferon-α Efficient delivery means (because delivery other route is difficult). Controlled release. 
Overcome stability problem.   
9 Norgesterol Improved transdermal flux 
10 Tamoxifen Improved transdermal flux 
11 Methotrexate Improved transdermal flux 
12 Oestradiol Improved transdermal flux 
13 Tetracaine, Lignocain Suitable means for the noninvasive treatment of local pain on direct topical drug 
application.   
14 Corticosteroids Improved site specificity and overall drug safety. 
15 Hydrocortisone 
Biologically active at dose several times lower than currently used formulation.   
16 Triamcinolone acetonide Used for both local and systemic delivery. 
17 
Human serum albumin Antibody titer is similar or even slightly higher than subcutaneous injection.  
18 
Stavudine Improved the in vitro skin delivery of Stavudine for antiretroviral activity   
19 Indinavir sulfate Enhanced Transdermal delivery  Indinavir sulphate for antiretroviral activity41 
20 Tetanus toxoid For transdermal immunization 
 
CONCLUSION  
Transdermal route of drug delivery does not allow transport 
of high mol.wt therapeutic agents and drugs because of the 
barrier properties of the stratum corneum layer of the skin. 
These Transferosomes are specially designed vesicles 
capable of responding to external stress by squeezing 
themselves through skin pores that are many times 
narrower than they are leading to increased transdermal flux 
of therapeutic agents. Transferosomes have beneficial 
advantages over other vesicular systems such as their high 
penetration power across skin, higher stability, systemic 
drug release possible and higher deformability than other 
vesicular systems such as niosomes, ethosomes etc., These 
will ensures reproducible and efficient transcutaneous 
carrier and drug transport. Transferosomes possess an 
infrastructure consisting of hydrophobic and hydrophilic 
moieties together and as a result can accommodate drug 
molecules with wide range of solubility. 
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